Kara Kelly is an Oncology physician affiliated with Women & Children's Hospital of Buffalo. OpenAlex indexes 405 publications with 9,993 citations (h-index 50); ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Elm And Carlton Streets
Buffalo, NY 142630001
Telephone
716-845-2300Provider last certified this registry record 20 Jan 2021.
Clinical trials
- MedSupport Intervention to Identify and Address Barriers to Pediatric Medication Adherence
Sponsor: Roswell Park Cancer Institute
- A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma
Sponsor: Children's Oncology Group
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Sponsor: National Cancer Institute (NCI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alexion Pharmaceuticals, Inc.Program year20251 payment
- Merck Sharp & Dohme LLCProgram year20241 payment$40,833openpaymentsdata.cms.gov ↗
- Fennec Pharmaceuticals, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
4 NIH research awards on record, funded 2013–2026 per NIH RePORTER. The latest:
- MedSupport: A Novel Multilevel Intervention to Identify and Address Barriers to Pediatric Medication
Roswell Park Cancer Institute Corp
FY2026$640,437R01CA283501 - MedSupport: A Novel Multilevel Intervention to Identify and Address Barriers to Pediatric Medication
Roswell Park Cancer Institute Corp
FY2026$31,622R01CA283501 - MedSupport: A Novel Multilevel Intervention to Identify and Address Barriers to Pediatric Medication
Roswell Park Cancer Institute Corp
FY2025$648,940R01CA283501
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma
New England Journal of Medicine
2022 - Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001
Journal of Clinical Oncology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Veetai Li, MD
Women & Children's Hospital of Buffalo
James Springate, MD
Women & Children's Hospital of Buffalo
Teresa Hennon, MD
Women & Children's Hospital of Buffalo
Christine Albini, MD, PH
Women & Children's Hospital of Buffalo
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”